Background
Methods
Study material
Immunohistochemistry
Image analysis
Statistical analysis
Results
Patient characteristics
Characteristics of control subjects and CF patients | |||
Control subjects
|
CF patients
|
p-value
| |
Number of patients (n)
| 22 | 20 | |
Female gender (n)
| 10 (45%) | 10 (50%) | 0.77 |
Mean age (±SEM) (years)
| 61.0 (±2.7) | 29.5 (±3.5) |
<0.0001***
|
Characteristics of male and female CF patients | |||
Male
|
Female
|
p-value
| |
Number of patients (n) (%)
| 10 (50%) | 10 (50%) | 1.00 |
Mean age (±SEM) (years)
| 31.6 (±3.5) | 27.3 (±6.1) | 0.052 |
Mean FEV
1
(±SEM) (% predicted)
| 25.6 (±2.3) | 30.6 (±1.5) | 0.052 |
CFTR genotype (n) (%)
| |||
ΔF508/ΔF508
| 4 (40%) | 6 (60%) | 0.30 |
ΔF508/other
| 4 (40%) | 4 (40%) | |
other/other
| 2 (20%) | 0 (0%) | |
Nasal polyposis (n) (%)
| 4 (40%) | 2 (20%) | 0.33 |
High urgency listing prior to LTx (n) (%)
| 1 (10%) | 4 (40%) | 0.12 |
Time on waiting list prior to LTx (±SEM) (days)
| 270.6 (±147.2) | 139.6 (±61.8) | 0.25 |
CRP (±SEM) (mg/L)
| 50.5 (±31.0) | 28.0 (±8.4) | 0.80 |
Differential eosinophil count on total WBC (±SEM) (%)
| 2.2 (±0.9) | 2.1 (±0.8) | 0.97 |
Total IgE (±SEM) (kU/L)
| 89.2 (±38.0) | 55.8 (±14.3) | 0.91 |
Colonization with P. aeruginosa (n) (%)
| 8 (80%) | 6 (60%) | 0.33 |
Fungi cultured from explant lung material (n) (%)
| 7 (70%) | 6 (60%) | 0.64 |
Use of inhaled corticosteroids (n) (%)
| 7 (70%) | 7 (70%) | 1.00 |
Use of oral corticosteroids (n) (%)
| 2 (20%) | 1 (10%) | 0.39 |
Time to last pre-LTx I.V. AB therapy (± SEM) (days)
| 48.5 (±19.1) | 77.9 (±61.0) | 0.48 |
Myeloid cell quantification and localization in end-stage CF lung tissue
Myeloid cell quantification and localization (expressed as cells/HPF) | |||
---|---|---|---|
Controls
|
CF
|
p-value
| |
Neutrophils (MPO)
| 17.4 (7.1–30.5) | 33.7 (25.4–47.8) |
0.0024**
|
Airway
| 15.1 (6.3–28.7) | 67.5 (43.5–81.9) |
<0.0001***
|
Parenchyma
| 19.7 (7.1–40.6) | 28.9 (15.3–36.6) | 0.18 |
Perivascular
| 9.7 (3.5–19.4) | 15.2 (9.2–18.9) | 0.18 |
Eosinophils (EG-2)
| 1.0 (0.4–2.9) | 2.3 (0.3–5.0) | 0.82 |
Airway
| 1.7 (0.6–5.5) | 2.0 (0.5–7.7) | 0.10 |
Parenchyma
| 1.1 (0.3–2.7) | 1.1 (0.1–3.6) | 0.63 |
Perivascular
| 0.6 (0.1–1.7) | 0.4 (0.0–2.0) | 0.61 |
Mast cell (tryptase)
| 10.5 (8.8–14.4) | 17.6 (12.5–24.7) |
0.018*
|
Airway
| 18.8 (15.3–31.2) | 25.2 (19.9–36.6) | 0.21 |
Parenchyma
| 7.8 (5.0–9.2) | 15.0 (8.8–21.3) |
0.0024**
|
Perivascular
| 9.3 (6.9–11.1) | 12.5 (9.9–15.8) |
0.0082**
|
Dendritic cells (CD1a)
| 0.8 (0.4–1.5) | 3.0 (2.1–4.2) |
<0.0001***
|
Airway
| 2.3 (0.8–3.6) | 4.7 (3.0–6.3) |
0.0013**
|
Parenchyma
| 0.2 (0.0–0.5) | 2.2 (1.0–3.8) |
<0.0001***
|
Perivascular
| 0.7 (0.1–2.0) | 1.6 (0.9–3.5) |
0.012*
|
Dendritic cells (CD207)
| 1.0 (0.3–1.8) | 4.6 (3.7–7.6) |
<0.0001***
|
Airway
| 3.0 (1.6–4.7) | 9.6 (7.6–13.2) |
<0.0001***
|
Parenchyma
| 0.0 (0.0–0.2) | 2.7 (1.1–5.9) |
<0.0001***
|
Perivascular
| 0.1 (0.0–0.4) | 1.2 (0.5–4.0) |
0.0001***
|
Macrophages (CD163)
| 18.7 (10.3–25.1) | 32.0 (23.0–39.8) |
0.0021**
|
Airway
| 15.5 (8.7–26.6) | 33.8 (18.4–40.4) |
0.0049**
|
Parenchyma
| 21.3 (10.6–26.8) | 35.0 (21.9–46.8) |
0.011*
|
Perivascular
| 16.9 (11.0–21.0) | 22.4 (14.1–31.6) | 0.064 |
Lymphoid cell and follicle quantification and localization in end-stage CF lung tissue
Lymphoid cell and follicle quantification (expressed as cells or follicles/mm2 area) | |||
---|---|---|---|
Control subjects
|
CF patients
|
Mann-Whitney U test
| |
CD4 T cells
| 3.8 (0.6–7.6) | 9.0 (2.9–21.7) |
0.007**
|
Cytotoxic T cells (CD8)
| 1.5 (0.2–11.4) | 55.8 (23.7–71.5) |
<0.0001***
|
B cells (CD20)
| 0.0 (0.0–0.9) | 0.3 (0.1–0.8) | 0.091 |
Lymphoid follicles
| 0.0 (0.0–0.009) | 0.056 (0.022–0.082) |
<0.0001***
|
Airway
| 0.0 (0.0–0.003) | 0.014 (0.006–0.029) |
<0.0001***
|
Parenchyma
| 0.0 (0.0–0.003) | 0.011 (0.006–0.039) |
<0.0001***
|
Perivascular
| 0.0 (0.0–0.003) | 0.011 (0.004–0.023) |
0.0002***
|
Myeloid and lymphoid cell quantification in the male and female CF subpopulation
Myeloid and lymphoid cell type quantification in the male and female CF patient subpopulation compared to control subjects | ||||
---|---|---|---|---|
Control subjects
|
Male CF patients
|
Female CF patients
|
ANOVA
| |
Neutrophils (MPO)
| 17.4 (7.1–30.5) | 30.1 (25.4–45.5) | 36.3 (24.0–51.8)* |
0.0009
|
Eosinophils (EG-2)
| 1.0 (0.4–2.9) | 0.3 (0.1–2.3) | 4.7 (1.8–9.6)§§
|
0.004
|
Mast cells (tryptase)
| 10.5 (8.8–14.4) | 12.5 (7.9–16.5) | 23.0 (18.7–32.3)***, §§
|
0.0005
|
Dendritic cells (CD1a)
| 0.8 (0.4–1.5) | 2.2 (1.5–3.9)* | 3.6 (2.7–6.6)*** |
<0.0001
|
Dendritic cells (CD207)
| 1.0 (0.3–1.8) | 4.3 (3.3–8.0)*** | 5.2 (2.8–14.3)*** |
<0.0001
|
Macrophages (CD163)
| 18.7 (10.3–25.1) | 33.5 (23.2–43.2)** | 26.9 (16.7–40.5) |
0.0058
|
CD4 T cells
| 3.8 (0.6–7.6) | 2.9 (1.2–7.1) | 21.7 (10.8–29.8)***, §§
|
<0.0001
|
Cytotoxic T cells (CD8)
| 1.5 (0.2–11.4) | 23.7 (12.7–58.6)* | 71.5 (48.1–115.0)*** |
<0.0001
|
B cells (CD20)
| 0.0 (0.0–0.9) | 0.5 (0.0–1.3) | 0.3 (0.1–0.6) | 0.21 |
Lymphoid follicles
| 0.0 (0.0–0.009) | 0.04 (0.01–0.1)*** | 0.065 (0.028–0.071)*** |
<0.0001
|